Related Experiment Video
Updated: Sep 30, 2025
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
Neuroendocrine tumor theranostics
Yasushi Ichikawa1, Noritoshi Kobayashi1, Shoko Takano2
1Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abstract:
Theranostics is a term coined by combining the words "therapeutics" and "diagnostics," referring to single chemical entities developed to deliver therapy and diagnosis simultaneously. Neuroendocrine tumors are rare cancers that occur in various organs of the body, and they express neuroendocrine factors such as chromogranin A and somatostatin receptor. Somatostatin analogs bind to somatostatin receptor, and when combined with diagnostic radionuclides, such as gamma-emitters, are utilized for diagnosis of neuroendocrine tumor. Somatostatin receptor scintigraphy when combined with therapeutic radionuclides, such as beta-emitters, are effective in treating neuroendocrine tumor as peptide receptor radionuclide therapy. Somatostatin receptor scintigraphy and peptide receptor radionuclide therapy are some of the most frequently used and successful theranostics for neuroendocrine tumor. In Japan, radiopharmaceuticals are regulated under a complex law system, creating a significant drug lag, which is a major public concern. It took nearly 10 years to obtain the approval for somatostatin receptor scintigraphy and peptide receptor radionuclide therapy use by the Japanese government. In 2021, 111 Lu-DOTATATE (Lutathera), a drug for peptide receptor radionuclide therapy, was covered by insurance in Japan. In this review, we summarize the history of the development of neuroendocrine tumor theranostics and theranostics in general, as therapeutic treatment for cancer in the future. Furthermore, we briefly address the Japanese point of view regarding the development of new radiopharmaceuticals.
Insights
Theranostics combines therapeutics and diagnostics for simultaneous treatment and imaging. For neuroendocrine tumors, somatostatin receptor-targeted agents offer effective diagnosis and peptide receptor radionuclide therapy.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Development
Background:
- Theranostics integrates therapeutic and diagnostic capabilities within single molecular agents.
- Neuroendocrine tumors (NETs) express specific receptors, like somatostatin receptors, making them suitable for targeted theranostic approaches.
- Somatostatin analogs are key in NET theranostics, enabling both imaging and targeted radionuclide therapy.
Purpose of the Study:
- To review the development and application of theranostics for neuroendocrine tumors.
- To highlight the clinical utility of somatostatin receptor scintigraphy and peptide receptor radionuclide therapy (PRRT) in NET management.
- To discuss the regulatory landscape and drug lag challenges for radiopharmaceuticals in Japan.
Main Methods:
- Review of literature on theranostics, focusing on NETs.
- Analysis of the role of somatostatin analogs in diagnostic imaging (scintigraphy) and therapeutic applications (PRRT).
- Examination of the historical development and regulatory approval process for radiopharmaceuticals in Japan.
Main Results:
- Somatostatin receptor scintigraphy and PRRT are established, effective theranostic modalities for NETs.
- The development and approval of radiopharmaceuticals in Japan face significant regulatory hurdles and delays.
- Recent progress includes insurance coverage for 177Lu-DOTATATE (Lutathera) in Japan in 2021.
Conclusions:
- Theranostics represents a significant advancement in cancer therapy, particularly for NETs.
- Overcoming regulatory challenges is crucial for timely patient access to novel radiopharmaceuticals.
- Continued development of theranostic agents holds promise for future cancer treatment strategies.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
